Adel R. Rizkala

15.6k total citations · 3 hit papers
41 papers, 7.3k citations indexed

About

Adel R. Rizkala is a scholar working on Cardiology and Cardiovascular Medicine, Pulmonary and Respiratory Medicine and Hematology. According to data from OpenAlex, Adel R. Rizkala has authored 41 papers receiving a total of 7.3k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Cardiology and Cardiovascular Medicine, 11 papers in Pulmonary and Respiratory Medicine and 10 papers in Hematology. Recurrent topics in Adel R. Rizkala's work include Heart Failure Treatment and Management (28 papers), Cardiovascular Function and Risk Factors (13 papers) and Cardiac pacing and defibrillation studies (8 papers). Adel R. Rizkala is often cited by papers focused on Heart Failure Treatment and Management (28 papers), Cardiovascular Function and Risk Factors (13 papers) and Cardiac pacing and defibrillation studies (8 papers). Adel R. Rizkala collaborates with scholars based in United States, United Kingdom and Sweden. Adel R. Rizkala's co-authors include John J.V. McMurray, Michael R. Zile, Scott D. Solomon, Jean L. Rouleau, Victor Shi, Milton Packer, Karl Swedberg, Martin Lefkowitz, Akshay S. Desai and Jianjian Gong and has published in prestigious journals such as New England Journal of Medicine, Circulation and Journal of the American College of Cardiology.

In The Last Decade

Adel R. Rizkala

38 papers receiving 7.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

2014 4.3k citations John J.V. McMurray, Milton Packer et al. New England Journal of Medicine profile →
Dual Angiotensin Receptor and Neprilysin Inhibition as an Alternative to Angiotensin-Converting Enzyme Inhibition in Patients with Chronic Systolic Heart Failure: Rationale for and Design of the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure Trial (PARADIGM-HF)

2013 339 citations John J.V. McMurray, Milton Packer et al. European Journal of Heart Failure profile →
Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients

2015 302 citations Akshay S. Desai, John J.V. McMurray et al. European Heart Journal profile →

Peers

Countries citing papers authored by Adel R. Rizkala

Since Specialization

Citations

This map shows the geographic impact of Adel R. Rizkala's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adel R. Rizkala with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adel R. Rizkala more than expected).

Fields of papers citing papers by Adel R. Rizkala

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adel R. Rizkala. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adel R. Rizkala. The network helps show where Adel R. Rizkala may publish in the future.

Co-authorship network of co-authors of Adel R. Rizkala

This figure shows the co-authorship network connecting the top 25 collaborators of Adel R. Rizkala. A scholar is included among the top collaborators of Adel R. Rizkala based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adel R. Rizkala. Adel R. Rizkala is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Comprehensive Analysis of the Effects of Sacubitril/Valsartan According to Sex Among Patients With Heart Failure and Reduced Ejection Fraction in PARADIGM‐HF 2025 ·Journal of the American Heart Association ·Misato Chimura, Jawad H. Butt, Shingo Matsumoto, (unknown), Alasdair Henderson, Atefeh Talebi, Akshay S. Desai, Marty Lefkowitz, Adel R. Rizkala, Jean-Lucien Rouleau, Scott D. Solomon, Karl Swedberg, Michael R. Zile, Milton Packer, Pardeep S. Jhund, John J.V. McMurray	1
2	Effects of Sacubitril/Valsartan According to Background Beta-Blocker Therapy in Patients with Heart Failure and Reduced Ejection Fraction: Insights from PARADIGM-HF 2024 ·European Journal of Heart Failure ·Shruti Gupta, Jawad H. Butt, (unknown), Atefeh Talebi, Shingo Matsumoto, Adel R. Rizkala, Alasdair Henderson, Akshay S. Desai, Marty Lefkowitz, Milton Packer, (unknown), Scott Solomon, Karl Swedberg, Michael R. Zile, Pardeep S. Jhund, John J.V. McMurray	0
3	Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan 2021 ·Circulation Heart Failure ·Luís Eduardo Paim Rohde, Brian Claggett, Emil Wolsk, Milton Packer, Michael R. Zile, Karl Swedberg, Jean L. Rouleau, Marc A. Pfeffer, Akshay S. Desai, Lars H. Lund, Lars Køber, Inder S. Anand, Béla Merkely, Michele Senni, Victor Shi, Adel R. Rizkala, Martin Lefkowitz, John J.V. McMurray, Scott D. Solomon	14
4	Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM‐HF 2021 ·Journal of the American Heart Association ·Solmaz Ehteshami‐Afshar, Leanne Mooney, Pooja Dewan, Akshay S. Desai, Ninian N. Lang, Martin Lefkowitz, Mark C. Petrie, Adel R. Rizkala, Jean L. Rouleau, Scott D. Solomon, Karl Swedberg, Victor Shi, Michael R. Zile, Milton Packer, John J.V. McMurray, Pardeep S. Jhund, Nathaniel M. Hawkins	27
5	Incidence and Outcomes of Pneumonia in Patients With Heart Failure 2021 ·Journal of the American College of Cardiology ·Li Shen, Pardeep S. Jhund, Inder S. Anand, Ankeet S. Bhatt, Akshay S. Desai, Aldo P. Maggioni, Felipe A. Martínez, Marc A. Pfeffer, Adel R. Rizkala, Jean L. Rouleau, Karl Swedberg, Muthiah Vaduganathan, Orly Vardeny, Dirk J. van Veldhuisen, Faı̈ez Zannad, Michael R. Zile, Milton Packer, Scott D. Solomon, John J.V. McMurray	45
6	Worsening Heart Failure Episodes Outside a Hospital Setting in Heart Failure With Preserved Ejection Fraction 2021 ·JACC Heart Failure ·Muthiah Vaduganathan, Jonathan W. Cunningham, Brian Claggett, (unknown), Ebrahim Barkoudah, Peter Finn, Faı̈ez Zannad, Marc A. Pfeffer, Adel R. Rizkala, (unknown), John J.V. McMurray, Scott D. Solomon, Akshay S. Desai	25
7	Relationship Between Duration of Heart Failure, Patient Characteristics, Outcomes, and Effect of Therapy in PARADIGM-HF 2020 ·ESC Heart Failure ·Su Ern Yeoh, Pooja Dewan, Akshay S. Desai, Scott D. Solomon, Jean L. Rouleau, Marty Lefkowitz, Adel R. Rizkala, Karl Swedberg, Michael R. Zile, Pardeep S. Jhund, Milton Packer, John J.V. McMurray	9
8	A PUTATIVE PLACEBO ANALYSIS OF THE EFFECTS OF SACUBITRIL/VALSARTAN IN HEART FAILURE ACROSS THE FULL RANGE OF EJECTION FRACTION 2020 ·Journal of the American College of Cardiology ·Muthiah Vaduganathan, Brian Claggett, Milton Packer, J Widimský, Petar Seferović, Adel R. Rizkala, Martin Lefkowitz, Victor Shi, John J.V. McMurray, Scott D. Solomon	1
9	Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF 2020 ·Journal of the American College of Cardiology ·Jonathan W. Cunningham, Brian Claggett, Eileen O’Meara, Margaret F. Prescott, (unknown), Sanjiv J. Shah, Margaret M. Redfield, Faı̈ez Zannad, Lu‐May Chiang, Adel R. Rizkala, Victor Shi, Marty Lefkowitz, Jean L. Rouleau, John J.V. McMurray, Scott D. Solomon, Michael R. Zile	83
10	Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction 2019 ·Journal of the American College of Cardiology ·Amil M. Shah, Maja Čikeš, Narayana Prasad, Guichu Li, (unknown), Brian Claggett, Adel R. Rizkala, (unknown), Eileen O’Meara, John Ryan, Sanjiv J. Shah, (unknown), Michael R. Zile, Carolyn S.P. Lam, John J.V. McMurray, Scott D. Solomon	152
11	Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF 2015 ·European Heart Journal ·Pardeep S. Jhund, Michael Fu, (unknown), Chen-Huan Chen, Marta Negrusz‐Kawecka, (unknown), Akshay S. Desai, Martin Lefkowitz, Adel R. Rizkala, Jean L. Rouleau, Victor Shi, Scott D. Solomon, Karl Swedberg, Michael R. Zile, John J.V. McMurray, Milton Packer	175
12	Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients breakdown → 2015 ·European Heart Journal ·Akshay S. Desai, John J.V. McMurray, Milton Packer, Karl Swedberg, Jean L. Rouleau, Fabian Chen, Jianjian Gong, Adel R. Rizkala, Abdel Brahimi, Brian Claggett, Peter Finn, L. Howard Hartley, Jiankang Liu, Martin Lefkowitz, Victor Shi, Michael R. Zile, Scott D. Solomon	302
13	Comparing LCZ696 With Enalapril According to Baseline Risk Using the MAGGIC and EMPHASIS-HF Risk Scores 2015 ·Journal of the American College of Cardiology ·Joanne Simpson, Pardeep S. Jhund, José Silva‐Cardoso, Felipe Martínez‐Pastor, Arend Mosterd, Félix José Alvarez Ramires, Adel R. Rizkala, Michele Senni, Iain Squire, Jianjian Gong, Martin Lefkowitz, Victor Shi, Akshay S. Desai, Jean L. Rouleau, Karl Swedberg, Michael R. Zile, John J.V. McMurray, Milton Packer, Scott D. Solomon	100
14	Baseline Characteristics and Treatment of Patients in Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF) 2014 ·European Journal of Heart Failure ·John J.V. McMurray, Milton Packer, Akshay S. Desai, Jianjian Gong, Martin Lefkowitz, Adel R. Rizkala, Jean L. Rouleau, Victor Shi, Scott D. Solomon, Karl Swedberg, Michael R. Zile	139
15	Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure breakdown → 2014 ·New England Journal of Medicine ·John J.V. McMurray, Milton Packer, Akshay S. Desai, Jianjian Gong, Martin Lefkowitz, Adel R. Rizkala, Jean L. Rouleau, Victor Shi, Scott D. Solomon, Karl Swedberg, Michael R. Zile	4343
16	Dual Angiotensin Receptor and Neprilysin Inhibition as an Alternative to Angiotensin-Converting Enzyme Inhibition in Patients with Chronic Systolic Heart Failure: Rationale for and Design of the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure Trial (PARADIGM-HF) breakdown → 2013 ·European Journal of Heart Failure ·John J.V. McMurray, Milton Packer, Akshay S. Desai, (unknown), Martin Lefkowitz, Adel R. Rizkala, Jean L. Rouleau, Victor Shi, Scott D. Solomon, Karl Swedberg, Michael R. Zile	339
17	Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation 2007 ·Kidney International ·Ajay Singh, Daniel W. Coyne, Warren Shapiro, Adel R. Rizkala, (unknown)	77
18	Iron sucrose causes greater proteinuria than ferric gluconate in non-dialysis chronic kidney disease 2007 ·Kidney International ·Rajiv Agarwal, Adel R. Rizkala, (unknown), (unknown), J. Richard Trout	33
19	Ferric Gluconate Is Highly Efficacious in Anemic Hemodialysis Patients with High Serum Ferritin and Low Transferrin Saturation 2007 ·Journal of the American Society of Nephrology ·Daniel W. Coyne, Toros Kapoian, Wadi N. Suki, Ajay Singh, John Moran, Naomi V. Dahl, Adel R. Rizkala	289
20	Functional iron deficiency in hemodialysis patients with high ferritin 2007 ·Hemodialysis International ·Robert C. Kopelman, (unknown), (unknown), (unknown), Adel R. Rizkala	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact